Journals / Ankara Üniversitesi Veteriner Fakültesi Dergisi / 2019 / Cilt: 66 - Sayı: 4

Oxidative status of colitis-associated cancer model induced by azoxymethane /dextran sulfate sodium and the effects of COX-2 inhibitor in mice

Farelerde azoksimetan /dekstran sülfat sodyum ile oluşturulan kolit ile ilişkili kanser modelinde oksidatif durum ve COX-2 inhibitörünün etkileri

Pages
351–356
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Meloxicam and /or AOM/DSS treatment not caused lipid peroxidations, but increased the antioxidant enzymes and Advanced Oxidation Protein Products levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Natural products and anti-inflammatory agents including cyclooxygenase-2 (COX-2) inhibitors which is a type of nonsteroidal anti-inflammatory drugs (NSAIDs) are highly considerable interest for the prevention of carcinogenesis.
📊
Key Findings & Data:The objective of this study is to evaluate the oxidative status of colitis-associated cancer induced by azoxymethane (AOM)/dextran sulfate sodium (DSS), and the effects of COX-2 inhibitor in mice.
💡
Conclusion & Impact:Meloxicam and /or AOM/DSS treatment not caused lipid peroxidations, but increased the antioxidant enzymes and Advanced Oxidation Protein Products levels.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Natural products and anti-inflammatory agents including cyclooxygenase-2 (COX-2) inhibitors which is a type of nonsteroidal anti-inflammatory drugs (NSAIDs) are highly considerable interest for the prevention of carcinogenesis. The objective of this study is to evaluate the oxidative status of colitis-associated cancer induced by azoxymethane (AOM)/dextran sulfate sodium (DSS), and the effects of COX-2 inhibitor in mice. Totally 40 mice were randomized and divided to four groups. All animals except control and Cox-2 inhibitor alone group received AOM/DSS to establish colitis-associated cancer model as reported elsewhere. COX-2 preferential inhibitor meloxicam was used to minimize side effects such as gastrointestinal hemorrhage. Meloxicam were used (5mg/kg, intraperitoneal) three times a week with meloxicam alone and AOM/DSS + meloxicam group. Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Malondialdehyde (MDA) and Advanced Oxidation Protein Products (AOPP) which all of them are oxidative stress markers were measured by spectrophotometrically. The combination treatment of Meloxicam and AOM/DSS significantly increased (P< 0.05) SOD activities in mice. GPx activities were found significantly increased (P< 0.05) in Meloxicam and AOM/DSS combinations or alone. There were no differences between the control and treatment groups of MDA levels. AOPP levels of Meloxicam and AOM/DSS combination group were found higher than the other groups. Meloxicam and /or AOM/DSS treatment not caused lipid peroxidations, but increased the antioxidant enzymes and Advanced Oxidation Protein Products levels.

Özet

Anti-inflamatuar ajanlar, selektif siklooksijenaz 2 inhibitörleri ve doğal moleküllerin karsinogenezin önlenmesinde kullanılması önemli araştırma ve ilgi alanını oluşturur. Bu çalışmanın amacı, farelerde azoksimetan (AOM)/dekstran sülfat sodyum (DSS) ile oluşturulan kolit ile ilişkili kanser modelinde oksidatif durum ve COX-2 inhibitörünün etkilerini araştırmaktır. Toplam 40 fare rastgele olarak dört gruba ayrıldı. Kontrol ve COX-2 inhibitörü alan gruplar hariç bütün gruplar daha önce bildirilen yönteme göre AOM/DSS uygulanarak kolit ile ilişkili kanser modeli oluşturuldu. Gastrointestinal hemoraji gibi yan etkileri minimize etmek için COX-2 seçici inhibitörü meloksikam kullanıldı. Meloksikam 5 mg/kg dozda haftada üç kez i.p. olarak uygulandı. Oksidatif stres belirteçleri süperoksit dismutaz (SOD), glutatyon peroksidaz (GPx), malondialdehit (MDA) ve ileri oksidasyon protein ürünleri (AOPP) spektrofotometrik olarak ölçüldü. Meloksikam ve AOM/DSS birlikte uygulaması farelerde SOD aktivitesine önemli düzeyde yükseltmiştir (P< 0.05). GPx aktivitesi meloksikam ve AOM/DSS tek ve kombine kullanımında önemli düzeyde artırmıştır (P< 0.05). MDA düzeyinde konrol grubu ile diğer gruplar arasında fark bulunmamıştır. AOPP seviyesi ise, meloksikam ve AOM/DSS kombine kullanıldığı grupta diğer gruplara göre daha yüksek bulundu. Meloksikam ve/veya AOM/DSS uygulaması lipid peroksidasyonuna neden olmazken, antioksidan enzim ve AOPP değerlerini yükselttiği görüldü.

🔖

Cite This Article

ÇAKIR, D. Ü., KOSOVA, F., ÜNER, A. G., SEL, T., SALMANOĞLU, B., MERAL, Ö., KISMALI, G., ALPAY, M. (2022). Oxidative status of colitis-associated cancer model induced by azoxymethane /dextran sulfate sodium and the effects of COX-2 inhibitor in mice. Ankara Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 66 - Sayı: 4, 351–356. https://ajindex.com/articles/444510

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Aggarwal B, Prasad S, Sung B, et al (2013): Prevention and treatment of colorectal cancer by natural agents from mother nature. Curr Colorectal Cancer Rep, 9, 37-56
  2. Alagozlu H, Gorgul A, Bilgihan A, et al (2013): Increased plasma levels of advanced oxidation protein products (AOPP) as a marker for oxidative stress in patients with active ulcerative colitis. Clin Res Hepatol Gastroenterol, 37, 80-85
  3. Ashokkumar P, Sudhandiran G (2008): Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother, 62, 590-597
  4. Baliga MS, Wang H, Zhuo P, et al (2007): Selenium and GPx-1 overexpression protect mammalian cells against UV-induced DNA damage. Biol Trace Elem Res, 115, 227-242
  5. Brigelius-Flohé R, Kipp A (2009): Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta, 1790, 1555-1568
  6. Cerutti P, Ghosh R, Oya Y, et al (1994): The role of the cellular antioxidant defense in oxidant carcinogenesis. Environ Health Perspect, 102, 123-129
  7. Das U (2002): A radical approach to cancer. Med Sci Monit, 4, 79-92
  8. Davies MJ, Fu S, Wang H, et al (1999): Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med, 11-12, 1151-1163
  9. Del Tacca M, Colucci R, Fornai M, et al (2002): Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug. Clin Drug Investig, 22, 799-818
  10. Diwadkar-Navsariwala V, Prins GS, Swanson SM, et al (2006): Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci USA, 103, 8179-8184
  11. Fajardo AM, Piazza GA (2015): Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol, 309, 59-70
  12. Hansen RD, Krath BN, Frederiksen K, et al (2009): GPX1 Pro(198)Leu polymorphism, erythrocyte GPX activity, interaction with alcohol consumption and smoking, and risk of colorectal cancer. Mutat Res, 664, 13-19
  13. Haug U, Poole EM, Xiao L, et al (2012): Glutathione peroxidase tagSNPs: associations with rectal cancer but not with colon cancer. Genes Chromosomes Cancer, 51, 598-605
  14. Heirman I, Ginneberge D, Brigelius-Flohé R, et al (2006): Blocking tumor cell eicosanoid synthesis by GP x 4 impedes tumor growth and malignancy. Free Radic Biol Med, 40, 285